Spontaneous regression of severe aortic stenosis after massive embolization in a patient with antiphospholipid syndrome

[1] Khamashta MA, Amigo MC. Antiphospholipid syndorme: overview of pathogenesis, diagnosis, and management. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME,Weisman MH, editors. Rheumatology, 6. Vol. 2. Philadelphia: Elsevier; 2015. p. 1144–52.Search in Google Scholar

[2] Ruiz-Irastorza G, CrowtherM, BranchW, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498–509.10.1016/S0140-6736(10)60709-XSearch in Google Scholar

[3] Perez-Villa F, Font J, Azqueta M, Espinosa G, Pare C, Cervera R, et al. Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, follow up study. Arthritis Rheum 2005;53:460–7.10.1002/art.21162Search in Google Scholar

[4] Gabrielli F, Alcini E, di Prima MA, Mazzacurati G, Masala C. Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies. Int J Cardiol 1995;51:117–26.10.1016/0167-5273(95)02357-3Search in Google Scholar

[5] Borowski A, Ghodsizad A, Cohnen M, Gams E. Recurrent embolism in the course of marantic endocarditis. Ann Thorac Surg 2005;79:2145–7.10.1016/j.athoracsur.2003.12.024Search in Google Scholar

[6] Eiken PW, Edwards WD, Tazelaar HD, McBane RD, Zehr KJ. Surgical pathology of nonbacterial thrombotic endocarditis in 30 patients, 1985–2000. Mayo Clin Proc 2001;76:1204–12.10.4065/76.12.1204Search in Google Scholar

[7] Moyssakis I, Tzioufas A, Triposkiadis F, Strateges N, Kyriakidis M. Severe aortic stenosis and mitral regurgitation in a woman with systemic lupus erythematosus. Clin Cardiol 2002;4:194–6.10.1002/clc.4960250412Search in Google Scholar

[8] Muscal E, Brey RL. Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons. Curr Rheumatol Rep 2008;10:67–73.10.1007/s11926-008-0012-ySearch in Google Scholar

[9] Denas G, Jose SP, Bracco A, Zoppellaro G, Pengo V. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015;14:214–22.10.1016/j.autrev.2014.11.003Search in Google Scholar

[10] Jouhikainen T, Pohjola-Sintonen S, Stephansson E. Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus 1994;3:167–72.10.1177/096120339400300307Search in Google Scholar

[11] Leung WH, Wong KL, Lau CP, Wong CK, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990;89:411–9.10.1016/0002-9343(90)90368-NSearch in Google Scholar

[12] Espínola-Zavaleta N, Vargas-Barrón J, Colmenares-Galvis T, Cruz-Cruz F, Romero-Cárdenas A, Keirns C, et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J 1999;137:973–8.10.1016/S0002-8703(99)70424-2Search in Google Scholar

[13] Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman–Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996;93:1579–87.10.1161/01.CIR.93.8.1579Search in Google Scholar

[14] Morelli S, Bernardo ML, Viganego F, Sgreccia A, De Marzio P, Conti F, et al. Left-sided heart valve abnormalities and risk of ischemic cerebrovascular accidents in patients with systemic lupus erythematosus. Lupus 2003;12:805–12.10.1191/0961203303lu468oaSearch in Google Scholar

[15] Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996;335:1424–30.10.1056/NEJM199611073351903Search in Google Scholar

[16] Turiel M, Sarzi-Puttini P, Peretti R, Bonizzato S, Muzzupappa S, Atzeni F, et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol 2005;96:574–9.10.1016/j.amjcard.2005.04.022Search in Google Scholar

[17] Dentali F, Manfredi E, Crowther M, Ageno W. Longduration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost 2005;3:2121–3.10.1111/j.1538-7836.2005.01516.xSearch in Google Scholar

[18] Sciascia S, Khamashta MA, D’Cruz DP. Targeted therapy in antiphospholipid syndrome. Curr Opin Rheumatol 2014;26:269–75.10.1097/BOR.0000000000000051Search in Google Scholar

[19] Bakshi J, Stevens R. Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome. Lupus 2013;22:865–7.10.1177/0961203313491023Search in Google Scholar

[20] Dufrost V, Risse J, Zuily S, Wahl D. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. Curr Rheumatol Rep 2016;18:74.10.1007/s11926-016-0623-7Search in Google Scholar

[21] Cohen H, Hunt BJ, Efthymiou M, Arachchillage DJ, Mackie IJ, Clawson S, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomized, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016;3:426–36.10.1016/S2352-3026(16)30079-5Search in Google Scholar

[22] Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997;27:27–35.10.1016/S0049-0172(97)80034-0Search in Google Scholar

[23] Erdozain JG, Ruiz-Irastorza G, Segura MI, Amigo MC, Espinosa G, Pomar JL, et al. Cardiac Valve Replacement in Patients with Antiphospholipid Syndrome. Arthritis Care Res (Hoboken) 2012;64:1256–60.10.1002/acr.2167022422594Search in Google Scholar

[24] Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg 2008;33:168–81.10.1016/j.ejcts.2007.11.00418082413Search in Google Scholar